Precision Medicine is an approach to disease prevention, diagnosis and treatment that seeks to account for relevant differences between individuals or subgroups so that healthcare can be better matched to biological characteristics and clinical context. It commonly uses information such as genetic variation, molecular profiles, biomarkers, disease characteristics, treatment response and sometimes environmental or behavioural data. In oncology, for example, molecular testing can identify alterations in a tumour that help determine whether a targeted therapy is appropriate.
Precision Medicine does not mean that every person receives a completely unique treatment. Rather, it aims to identify biologically or clinically meaningful subgroups and select interventions according to characteristics that influence risk or response. It therefore depends on accurate measurement, validated biomarkers, reliable interpretation and evidence that using the information improves outcomes.
The development of Precision Medicine accelerated with advances in molecular biology, high-throughput sequencing, bioinformatics and computational analysis. The completion of the Human Genome Project and subsequent reductions in sequencing costs expanded the ability to investigate genetic variation at scale. Molecular characterisation of cancers demonstrated that tumours classified by the same anatomical site can have substantially different biological drivers and treatment responses. Similar principles have been applied to pharmacogenomics, rare disease diagnosis and some immune-mediated conditions.
The term became prominent in policy and research discussions during the early twenty-first century, including major initiatives designed to integrate large-scale biological and clinical datasets. Precision Medicine therefore represents an evolution in using molecular information to refine conventional clinical categories rather than a complete replacement for traditional clinical assessment.
Biomarkers are central to many Precision Medicine applications. A biomarker can provide measurable information about a biological process, disease state or response to treatment, but biomarkers have different roles. Diagnostic biomarkers assist in identifying disease, prognostic biomarkers provide information about expected disease outcomes, and predictive biomarkers help identify the likelihood of benefit from a particular treatment. These distinctions are important because a marker associated with disease severity is not necessarily a marker that predicts treatment response. Clinical validation requires demonstration that the biomarker is measured reliably and that using it changes management in a way that improves meaningful outcomes. Analytical validity, clinical validity and clinical utility are therefore distinct concepts that should not be conflated.
Cancer is a major field of Precision Medicine because tumour genomes can contain alterations that influence growth pathways and treatment sensitivity. Molecular testing may identify variants, gene fusions, amplification, deficiency in DNA repair processes or other characteristics relevant to therapy selection. However, detecting a molecular alteration does not automatically establish that a corresponding drug will work. Some alterations are predictive treatment biomarkers, while others are merely biologically interesting or prognostic. Tumours can also evolve under treatment, producing heterogeneity and acquired resistance. Precision oncology therefore requires repeated clinical and molecular interpretation rather than assuming that one genomic test permanently defines the tumour.
Pharmacogenomics is another important application. Genetic variants can affect drug metabolism, transport, receptor activity or immune responses, altering the probability of therapeutic benefit or adverse effects. For some medicines, genetic testing can inform dosing or identify people at increased risk of severe reactions. However, genetic information is only one determinant of drug response. Age, kidney and liver function, interacting medicines, disease state and adherence can also be important. Precision Medicine therefore works best when genomic data are integrated with conventional clinical information rather than treated as a standalone predictor. A clinically useful biomarker must be actionable in the context of the particular treatment decision.
Precision Medicine requires substantial infrastructure. Biological samples must be collected appropriately, laboratory assays need quality control, sequencing generates large datasets requiring computational interpretation, and results must be connected to clinically validated knowledge. Data standards and interoperability affect whether molecular findings can be incorporated into electronic clinical workflows. Variant interpretation can be difficult because many detected genetic changes have uncertain significance. Incidental findings can also create questions about whether unrelated clinically significant information should be reported. Privacy and governance are particularly important because genomic information can potentially reveal information about relatives as well as the person tested.
Precision Medicine is often confused with Personalised Medicine, and the terms are sometimes used interchangeably. Precision Medicine tends to emphasise measurable biological and clinical differences that can improve classification or treatment selection, particularly molecular and genomic characteristics. Personalised Medicine is broader in ordinary usage and can include individual preferences, circumstances and clinical characteristics in addition to biological information. Precision Medicine also differs from population-wide medicine not because it rejects population evidence but because it uses population research to identify differences that can guide more targeted decisions. A further misconception is that precision automatically means certainty; molecular data can improve classification while still leaving substantial uncertainty about prognosis or treatment response.
Precision Medicine can improve treatment selection, reduce exposure to ineffective therapies and reveal disease mechanisms that conventional categories obscure. Its limitations include cost, incomplete biomarker validation, tumour or disease heterogeneity, uncertain findings, unequal access and the possibility that molecular information has no actionable consequence. It also raises ethical and governance questions concerning consent, privacy, data sharing and potential discrimination. The practical value of Precision Medicine therefore depends on demonstrating clinical utility rather than merely generating increasingly detailed biological information. Its strongest applications occur where a validated characteristic meaningfully changes management and where evidence shows that acting on that characteristic improves outcomes.
